Tagged with Access

Poland Jarek Oleszczuk, country president of AstraZeneca Poland, the leading R&D investor in Poland, discusses the exciting milestones that the company has achieved, including reimbursement of two breakthrough oncology therapies, as well as the company’s addition of 500 staff, representing now a 1,150-strong workforce. Furthermore, he touches on AstraZeneca’s key role…

Poland Drago Vuina, corporate vice-president of Novo Nordisk Eastern Europe, highlights Poland as the most significant market in the region and the on-going commitment to make innovative treatment options available for patients. Furthermore, he discusses Novo Nordisk’s strong commitment to social responsibility in each country throughout the region and the need…

India A pioneer of the biotechnology industry in India and the head of the country’s leading biotechnology enterprise, Kiran Mazumdar-Shaw, discusses the recent US FDA approval of Ogivri™, the first biosimilar for trastuzumab and the sixth approved biosimilar in the US overall, and how Biocon is implementing a low-value high-volume model…

Switzerland Jeff Dufour, country manager Switzerland and BU lead Internal Medicine at Pfizer, discusses his first impressions of the country, his priorities for greater dialogue with Swiss healthcare insurers, and Switzerland’s potential as a ‘test market’ for the company. Can you give our international readers an outline of your background and…

Switzerland Petra Doerr, head of sector communication & networking as well as deputy executive director of Swissmedic, the Swiss surveillance authority for medicines and medical devices, discusses changes to the Swiss regulatory system and harmonizing the organization with its global counterparts. Swissmedic has embarked upon a comprehensive overhaul of its regulations in response…

Austria Albin Egger, country representative of UCB Pharma Austria, discusses the strong performance of the Austrian affiliate within the global group, organizational restructuring, and the receptiveness of Austria to UCB’s innovative products. Globally, UCB registered nine percent growth for the first nine months of 2017. How would you describe the contribution…

India With the Indian public healthcare apparatus straining at the seams to provide affordable access to treatments to the country’s vast population, two pioneering pharmaceutical multinationals – Novartis and Janssen – have stepped up with innovative initiatives to fill the gaps. “Economists such as Michael Porter see Arogya Parivar as a…

Lithuania Marijus Valatka, general manager Lithuania, Latvia and Estonia at Novo Nordisk, explains the current challenges and areas for improvement in diabetes treatment in Lithuania and stresses the company’s commitment to not only bring medicines to the market but also enhance the quality of treatment fort diabetes and other serious chronic…

Canada Colette Rivet, executive director of the Cannabis Canada Association, leading Canadian licensed medical cannabis producers, talks regulatory challenges, upcoming opportunities, export ambitions and collaboration with the provincial and federal government in light of the upcoming legalization of cannabis for adult use in Canada. Colette, can you introduce the Cannabis Canada…

Poland Wojciech Koziejowski, managing director of Lundbeck Poland, discusses attaining reimbursement in Poland for the first time in ten years and the recent set-up of their global shared service center of more than 200 staff in Krakow. Moreover, he highlights the leading role the company is taking in educating key stakeholders…

Lithuania Darius Sinkevičius, chairman of the board at the Lithuanian Association of Generic Pharmaceuticals Manufacturers (VGA), explains the main trends impacting the generic pharmaceutical industry in the country as well as the role of off-patent medicines in creating savings for the Lithuanian healthcare system. Can you give to our international audience…

Brazil Fraser Hall, country president of AstraZeneca Brazil, describes the current trends and dynamics shaping the Brazilian pharmaceutical market and documents the promising partnership opportunities he envisions to significantly increase patient access in both the private and public sectors. You were appointed country president of AstraZeneca Brazil in September 2016 after…